Brisbane ALIF Device, Gladstone ALIF Device
Device Facts
| Record ID | K172019 |
|---|---|
| Device Name | Brisbane ALIF Device, Gladstone ALIF Device |
| Applicant | Signature Orthopaedics Pty, Ltd. |
| Product Code | OVD · Orthopedic |
| Decision Date | Nov 29, 2017 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Signature Orthopaedics Brisbane ALIF and Gladstone ALIF systems are indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of nonoperative treatment. Patients with previous non-fusion spinal surgery at the treated level may be treated. These implants may be implanted via a laparoscopic or an open anterior approach. The Brisbane and Gladstone ALIF systems may be used as stand-alone devices or in conjunction with supplemental fixation. When used as a stand-alone device the subject devices must be used with all three screws.
Device Story
Intervertebral body fusion devices (cages) designed for lumbar spine stabilization. Cages feature wedge-shaped geometry to restore lordosis and hollow centers for autogenous bone graft loading. Brisbane and Gladstone systems include titanium alloy screws for stand-alone fixation; Brisbane cage includes titanium plasma spray coating. Implants are inserted by surgeons via open or laparoscopic anterior approach to treat degenerative disc disease. Devices provide structural support to vertebral bodies during fusion process. Benefit includes stabilization of spinal segments and potential reduction of discogenic back pain.
Clinical Evidence
No clinical data. Evidence consists of non-clinical bench testing and engineering evaluations, including Finite Element Analysis (FEA) to identify worst-case configurations. Testing included static/dynamic compression, compression shear (ASTM-F2077), subsidence (ASTM-F2267), and screw mechanical testing (ASTM-F543). Coating characterization performed per ASTM-F1580, F1854-09, F1044-05, F1147-05, F1160-05, and F1978-00.
Technological Characteristics
Cages: PEEK-OPTIMA LT1 (ASTM-F2026). Screws: Ti6Al4V alloy (ISO 5832-3, ASTM-F136). Brisbane cage coating: Titanium Plasma Spray (ASTM-F1580). Design: Wedge-shaped, hollow for bone graft, serrated surfaces. Stand-alone capability via three-screw fixation. Sterilization not specified.
Indications for Use
Indicated for skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1, including those with up to Grade I spondylolisthesis or retrolisthesis. Requires six months of failed nonoperative treatment. Used with autogenous bone graft via laparoscopic or open anterior approach.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
Predicate Devices
- Spine MIDLINE II-TiTM (K141942)
- Benvenue Medical Inc Luna 360 Interbody System (K142023)
- K2M Chesapeake Spinal System (K133494)
- Spineart DYNAMIK Lumbar Interbody Device (K081888)
Reference Devices
- Signature Orthopaedics NOOSA Anterior Lumbar Plate Screw (K163625)